Lubomir Sokol Selected Research

Peripheral Nervous System Diseases (PNS Diseases)

11/2023	Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma.
1/2019	Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
3/2014	Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lubomir Sokol Research Topics

Disease

27	Neoplasms (Cancer) 02/2024 - 08/2003
12	Lymphoma (Lymphomas) 01/2023 - 08/2003
12	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 09/2018 - 01/2006
10	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 05/2024 - 09/2010
10	Large Granular Lymphocytic Leukemia 10/2023 - 08/2003
7	T-Cell Lymphoma (Lymphoma, T Cell) 01/2023 - 08/2003
7	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 01/2022 - 01/2014
6	Infections 01/2023 - 09/2013
6	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 07/2009
6	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/2017 - 07/2012
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2024 - 12/2011
5	Mycosis Fungoides 01/2023 - 06/2014
5	Leukemia 01/2018 - 08/2003
4	Hodgkin Disease (Hodgkin's Disease) 11/2023 - 02/2017
4	Anemia 10/2023 - 11/2007
4	Thrombocytopenia (Thrombopenia) 01/2023 - 07/2002
4	Cytopenia 01/2018 - 08/2003
4	B-Cell Lymphoma (Lymphoma, B Cell) 09/2016 - 07/2012
3	Disease Progression 02/2024 - 08/2003
3	Peripheral Nervous System Diseases (PNS Diseases) 11/2023 - 03/2014
3	Fever (Fevers) 11/2023 - 07/2013
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022 - 08/2003
3	Lymphadenopathy 11/2020 - 04/2003
3	Multiple Myeloma 01/2018 - 12/2006
3	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2018 - 08/2014
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 10/2017 - 08/2010
2	Lung Injury 11/2023 - 01/2019
2	Neutropenia 11/2023 - 10/2023
2	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 01/2023 - 01/2016
2	Enteropathy-Associated T-Cell Lymphoma 01/2022 - 11/2017
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 01/2022 - 11/2017
2	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2019 - 01/2018
2	Sepsis (Septicemia) 01/2018 - 04/2003
2	Hepatitis B 01/2018 - 02/2017
2	Castleman Disease (Castleman's Disease) 07/2013 - 08/2010
2	Fatigue 07/2013 - 04/2013
2	Bone Marrow Failure Disorders 05/2012 - 02/2011
1	Plasmablastic Lymphoma 02/2024
1	COVID-19 06/2023
1	Blast Crisis (Blast Phase) 01/2023
1	Eosinophilia 01/2023
1	Inflammation (Inflammations) 01/2023
1	Leukopenia 01/2023
1	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 09/2022
1	Pathologic Complete Response 05/2021

Drug/Important Bio-Agent (IBA)

9	romidepsin (FK228)FDA Link 10/2019 - 02/2012
8	Lenalidomide (CC 5013)FDA Link 02/2024 - 12/2006
7	Histone Deacetylase InhibitorsIBA 01/2021 - 01/2014
6	Monoclonal AntibodiesIBA 01/2018 - 08/2010
5	Proteins (Proteins, Gene)FDA Link 09/2018 - 04/2005
5	Rituximab (Mabthera)FDA Link 10/2017 - 07/2012
4	Methotrexate (Mexate)FDA LinkGeneric 01/2023 - 08/2003
3	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2023 - 01/2016
3	mogamulizumabIBA 01/2022 - 03/2015
3	Vorinostat FDA Link 12/2020 - 01/2018
3	Hepatitis B Surface Antigens (HBsAg)FDA Link 01/2018 - 09/2013
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2016 - 08/2003
2	Biomarkers (Surrogate Marker)IBA 02/2024 - 09/2018
2	Brentuximab VedotinIBA 11/2023 - 01/2019
2	Bleomycin (Blenoxane)FDA LinkGeneric 11/2023 - 01/2019
2	Vinblastine (Vinblastine Sulfate)FDA Link 11/2023 - 01/2019
2	Dacarbazine (DIC)FDA LinkGeneric 11/2023 - 01/2019
2	CytokinesIBA 10/2023 - 04/2012
2	Etoposide (VP 16)FDA LinkGeneric 01/2023 - 01/2016
2	Tyrosine Kinase InhibitorsIBA 01/2023 - 04/2013
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2022
2	SteroidsIBA 01/2023 - 04/2017
2	Anaplastic Lymphoma KinaseIBA 01/2022 - 11/2017
2	MethyltransferasesIBA 01/2021 - 01/2021
2	pembrolizumabIBA 01/2020 - 01/2020
2	InflammasomesIBA 09/2018 - 12/2016
2	Antiviral Agents (Antivirals)IBA 01/2018 - 02/2017
2	Histone Deacetylases (Histone Deacetylase)IBA 06/2016 - 03/2016
2	siltuximabIBA 07/2013 - 08/2010
2	MicroRNAs (MicroRNA)IBA 03/2013 - 04/2011
2	EpitopesIBA 05/2012 - 04/2005
2	Peptides (Polypeptides)IBA 05/2012 - 04/2005
2	Farnesyltranstransferase (Farnesyltransferase)IBA 04/2012 - 12/2008
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 03/2006 - 08/2003
1	ofatumumab FDA Link 02/2024
1	Methylprednisolone FDA LinkGeneric 02/2024
1	B-Cell Maturation AntigenIBA 02/2024
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 11/2023
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2023
1	Asparaginase (Elspar)FDA Link 01/2023
1	Ifosfamide FDA LinkGeneric 01/2023
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2023
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023
1	cc-486IBA 01/2023
1	Inosine Triphosphate (ITP)IBA 09/2022
1	tagraxofuspIBA 01/2022
1	Carrier Proteins (Binding Protein)IBA 01/2021

Therapy/Procedure

44	Therapeutics 02/2024 - 04/2003
12	Drug Therapy (Chemotherapy) 02/2024 - 08/2003
8	Cell Transplantation 05/2024 - 11/2017
4	Induction Chemotherapy 01/2019 - 04/2003
3	Immunotherapy 01/2018 - 08/2014
2	Radiotherapy 06/2023 - 08/2003
2	Hematopoietic Stem Cell Transplantation 01/2019 - 01/2018
1	Secondary Prevention 01/2023